ArticleBMJ open2026

Single-arm, multicentre phase II trial of sintilimab plus platinum-based doublet chemotherapy followed by adaptive radiotherapy strategy for patients with unresectable stage III non-small-cell lung cancer in China: the ART-LUNG 01 study protocol.

Li Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.